Esperion Therapeutics Inc (NASDAQ:ESPR) has been given an average recommendation of “Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $87.36.
A number of analysts have recently weighed in on ESPR shares. BidaskClub raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 13th. UBS set a $88.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 17th. Credit Suisse Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price target for the company. Chardan Capital upped their price target on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, December 6th. Finally, Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price target for the company from $72.00 to $81.00 in a report on Thursday, December 14th.
Esperion Therapeutics (ESPR) traded down $1.00 during trading hours on Friday, hitting $76.53. 611,004 shares of the stock were exchanged, compared to its average volume of 698,298. Esperion Therapeutics has a 52 week low of $20.39 and a 52 week high of $82.68. The company has a market capitalization of $2,027.97, a PE ratio of -10.90 and a beta of 2.45.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.36. During the same quarter last year, the business posted ($1.29) earnings per share. research analysts forecast that Esperion Therapeutics will post -5.66 EPS for the current year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the company’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total value of $838,076.46. Following the completion of the transaction, the director now directly owns 3,177 shares in the company, valued at approximately $228,076.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 32.50% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $222,000. BB&T Securities LLC purchased a new position in Esperion Therapeutics during the 4th quarter worth approximately $263,000. First Mercantile Trust Co. grew its stake in Esperion Therapeutics by 56.0% during the 4th quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 1,519 shares during the last quarter. Creative Planning purchased a new position in Esperion Therapeutics during the 4th quarter worth approximately $314,000. Finally, Oakmont Partners LLC purchased a new position in Esperion Therapeutics during the 4th quarter worth approximately $323,000. Institutional investors and hedge funds own 91.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics Inc (ESPR) Given Consensus Recommendation of “Buy” by Brokerages” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/03/18/esperion-therapeutics-inc-espr-given-consensus-recommendation-of-buy-by-brokerages.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.